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MSC cells have demonstrated significant immunosuppressive effects in various in 
vivo and in vitro studies. This study aims to be the first evaluation of the safety and 
tolerability of third party MSC infusion after cadaveric kidney and liver transplantation 
in a prospective phase I-II study, taking advantage of our centre expertise and 
experience in MSC use in graft-versus-host disease (GVHD) after bone marrow 
transplantation and using an already functioning GMP-compliant laboratory 
producing clinical-grade MSC. Secondary end-points will help to evaluate the 
immunosuppressive potential of MSC after organ transplantation, and the opportunity 
to develop larger randomised, controlled, phase III trials. 
After successful transplantation, 10 liver and 10 kidney transplant recipients under 
standard immunosuppression (tacrolimus, MMF, steroids) will receive an intravenous 
infusion of 1.5-3x106/kg of third-party MSC on post-operative day 3±2. These 
patients will be prospectively compared to 10 liver and 10 kidney recipients who meet 
the inclusion criteria but deny MSC infusion. Safety will be assessed by recording 
side effects, including opportunistic infections and cancers. Immunosuppressive 
potential will be evaluated by rejection episode rates, by graft/patient survivals, by 
immunohistology of 3-months kidney and 6-month liver graft biopsies and by in vitro 
evaluation of the immunity profile of the recipients. In a second step, reduction 
(kidney) and progressive weaning (liver) of immunosuppression will be attempted in 
recipients who received MSC.  
This ongoing study is supported by research grants from the CHU of Liège, 
University of Liège, and by the Senior Clinical Research Grant from ESOT. The first 
patients were included and treated in early 2012, and final results expected in late 
2013. 
 
